Background: Over the last two decades, deep-sea-derived fungi are considered to
be a new source of pharmacologically active secondary metabolites for drug discovery mainly
based on the underlying assumption that the uniqueness of the deep sea will give rise to
equally unprecedented natural products. Indeed, up to now over 200 new metabolites have
been identified from deep-sea fungi, which is in support of the statement made above.
Results: This review summarizes the new and/or bioactive compounds reported from deepsea-
derived fungi in the last six years (2010 – October 2016) and critically evaluates whether
the data published so far really support the notion that these fungi are a promising source of
new bioactive chemical entities.
Keywords: Deep-sea fungi, extremophiles, natural products, bioactive metabolites, drug discovery, bioprospecting.
Rights & PermissionsPrintExport